Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics

25 May 2018

Abstract excerpt

// Sabrina Noack 1 , Monika Raab 1 , Yves Matthess 1, 2 , Mourad Sanhaji 1 , Andrea Krämer 1 , Balázs Győrffy 3, 5 , Lars Kaderali 4 , Ahmed El-Balat 1 , Sven Becker 1 and Klaus Strebhardt 1, 2 1 Department of Gynecology, Goethe-University, Frankfurt am Main, Germany 2 German Cancer Consortium DKTK, German Cancer Research Center, Heidelberg, Germany 3 MTA TTK Lendület Cancer Biomarker Research Group, Institute of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Microtubule and mitosis dynamics
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29899826
DOI: 10.18632/oncotarget.25386

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamicsPMID 29899826Read ↗

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeuticsSemantic proximity Read ↗

Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancerSemantic proximity Read ↗

Mitotic Poisons In Cancer PharmacotherapySemantic proximity Read ↗

Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality InductionSemantic proximity Read ↗

Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor SignalingSemantic proximity Read ↗

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in OncologySemantic proximity Read ↗

Synthetic lethality between <i>CCNE1</i> amplification and loss of <i>BRCA1</i>Semantic proximity Read ↗

Polo-like kinase-1 Inhibitors and the Antiandrogen Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor SignalingSemantic proximity Read ↗

A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing drugs in RB1-deficient ovarian and breast cancer cellsSemantic proximity Read ↗

Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivoSemantic proximity Read ↗

Mitotic Poisons in Research and MedicineSemantic proximity Read ↗

In-Silico Evaluation of Genetic Alterations in Ovarian Carcinoma and Therapeutic Efficacy of NSC777201, as a Novel Multi-Target Agent for TTK, NEK2, and CDK1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.